این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
صفحه اصلی
درباره پایگاه
فهرست سامانه ها
الزامات سامانه ها
فهرست سازمانی
تماس با ما
JCR 2016
جستجوی مقالات
چهارشنبه 3 دی 1404
گوارش
، جلد ۲۹، شماره ۳، صفحات ۱۵۷-۱۶۶
عنوان فارسی
چکیده فارسی مقاله
کلیدواژههای فارسی مقاله
عنوان انگلیسی
Hepatitis B Viral Markers and Immune Status in Patients with Inflammatory Bowel Diseases: A Cross-Sectional Study Using Data Mining Approach
چکیده انگلیسی مقاله
Background: Patients with inflammatory bowel diseases (IBDs) are at high risk of contracting hepatitis B virus (HBV) or its reactivation due to surgical procedures, blood transfusions, and immunosuppressive therapy. Little is known about the HBV immune status in patients with IBD. Objective: We aimed to evaluate the HBV serology of adult patients with IBD in Mashhad, northeastern Iran. Materials and Methods: A cross-sectional study was conducted among patients with IBD referred from Mashhad gastrointestinal clinics between June 2021 and August 2022. Demographic and other related data were collected. Hepatitis B surface antigen (HBS-Ag), hepatitis B surface antibody (anti-HBS Ab), and hepatitis B core protein antibody (anti-HBC Ab) were measured. Patients were classified into sub-groups of chronic HBV infection, past HBV infection, effective vaccination, and non-immune against HBV. A decision tree (DT) algorithm was applied to analyze data. Results also were performed using SPSS software version 23.0 at a significant level of 0.05. Results: 90 patients (30 with Crohn’s disease and 60 with ulcerative colitis) with an average age of 40.48±15.1 years were examined. 35.6% were men. The rate of past HBV infection and chronic HBV infection was 4.4% and 1.1%, respectively. Effective vaccination was 31.1%, and non-immunity against HBV was 63.4%. Use of biological agents was significantly higher among subjects with IBDs ≥10 years (P=0.032). The DT model showed that type of therapy, type of disease, and sex have the most effect on effective vaccination development and anti-HBS Ab level. Conclusion: We recommend fully vaccinating seronegative patients with IBD before the initiation of immunosuppressive therapy and routinely monitoring anti-HBS Ab levels, especially in patients under combined therapy.
کلیدواژههای انگلیسی مقاله
Hepatitis B virus, Inflammatory bowel diseases, Ulcerative colitis, Crohn’s disease, Decision tree
نویسندگان مقاله
| Rana Kolahi Ahari
Department of Internal Medicine, Faculty of Medical Sciences, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran
| Elham Mokhtari Amirmajdi
Department of Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran
| Amin Mansoori
Department of Gastroenterology and Hepatology, Mashhad University of Medical Sciences, Mashhad, Iran
| Mitra Ahadi
Department of Gastroenterology and Hepatology, Mashhad University of Medical Sciences, Mashhad, Iran
| Ali Bahari
Department of pathology, Faculty of Medical Sciences, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran
| Alireza Rezaei
نشانی اینترنتی
http://govaresh.org/index.php/dd/article/view/2653
فایل مقاله
فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
Original Article
برگشت به:
صفحه اول پایگاه
|
نسخه مرتبط
|
نشریه مرتبط
|
فهرست نشریات